Quantcast
Last updated on April 25, 2014 at 5:25 EDT

Latest PDS Biotechnology Corporation Stories

2013-04-16 20:23:11

LAWRENCEBURG, Ind., April 16, 2013 /PRNewswire/ -- PDS Biotechnology Corporation today presented a summary of the company's preclinical data on its lead cancer immunotherapy PDS0101 at the World Vaccine Congress in Washington DC. The product is based on the company's ground-breaking and proprietary Versamune(TM) nanotechnology vaccine platform. PDS Biotechnology also announced that the company's Investigational New Drug (IND) application had been granted by the FDA allowing PDS0101 to be...

2012-07-08 18:21:27

LAWRENCEBURG, Ind., July 9, 2012 /PRNewswire/ -- PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune(TM) nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific...

2010-03-02 06:00:00

INDIANAPOLIS, March 2 /PRNewswire/ -- PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010. This curative vaccine, which is based on PDS...

2009-10-06 06:00:00

LAWRENCEBURG, Ind., Oct. 6 /PRNewswire/ -- PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology. No signs of toxicity were observed at the highest doses...

2009-02-24 10:13:00

INDIANAPOLIS, Feb. 24 /PRNewswire/ -- PDS Biotechnology today announced that the company has obtained an exclusive license from Merck Eprova AG to utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV and other products in development based on the Versamune(TM) technology. The use of enantiomerically pure DOTAP Chloride shows enhanced adjuvant activity compared to the racemate. Merck Eprova AG will be providing enantiomerically pure DOTAP Chloride...

2008-11-06 15:00:06

CINCINNATI, Nov. 6 /PRNewswire/ -- PDS Biotechnology Corporation today announced that the company has been selected as a collaborator of the US National Cancer Institute's Nanotechnology Characterization Lab (NCL) to complete preclinical development of Versamune(TM)-HPV prior to filing of the Investigational New Drug Application. The NCL will perform selected physical, chemical and biological studies on behalf of the company at its facilities at the National Cancer Institute (NCI) in...